Timothy F Cloughesy Selected Research

vorasidenib

1/2021

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Timothy F Cloughesy Research Topics

Disease

140	Neoplasms (Cancer) 10/2022 - 09/2002
130	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 09/2002
91	Glioma (Gliomas) 10/2022 - 04/2002
46	Brain Neoplasms (Brain Tumor) 10/2022 - 01/2004
4	Hypoxia (Hypoxemia) 01/2022 - 05/2007
4	Diarrhea 01/2018 - 01/2004
4	Edema (Dropsy) 05/2013 - 05/2007
3	Meningioma (Meningiomas) 01/2010 - 12/2009
2	Oligodendroglioma 01/2021 - 10/2008
2	Astrocytoma (Pilocytic Astrocytoma) 12/2020 - 03/2014
2	Hypertension (High Blood Pressure) 01/2020 - 01/2018
2	Fatigue 01/2019 - 01/2018
2	Residual Neoplasm 01/2019 - 01/2018
2	Inflammation (Inflammations) 11/2015 - 01/2013
2	Leukemia 05/2014 - 03/2013

Drug/Important Bio-Agent (IBA)

28	Bevacizumab (Avastin)FDA Link 01/2021 - 06/2008
22	Pharmaceutical PreparationsIBA 10/2022 - 02/2004
22	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2008
22	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 02/2007
21	ErbB Receptors (EGF Receptor)IBA 05/2022 - 09/2002
20	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 05/2022 - 03/2012
13	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2005
13	Phosphotransferases (Kinase)IBA 01/2020 - 06/2003
13	epidermal growth factor receptor VIIIIBA 07/2015 - 09/2002
11	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2004
10	Biological ProductsIBA 01/2022 - 04/2003
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 05/2007
10	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2020 - 11/2005
10	EnzymesIBA 12/2019 - 01/2004
8	MethyltransferasesIBA 01/2022 - 01/2012
7	AminesIBA 06/2022 - 11/2015
7	fluorodopa F 18IBA 05/2021 - 08/2012
7	VaccinesIBA 10/2020 - 08/2005
7	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2019 - 07/2005
6	Amino Acids FDA Link 06/2022 - 05/2014
6	Tyrosine Kinase InhibitorsIBA 10/2020 - 10/2010
6	Mechanistic Target of Rapamycin Complex 2IBA 12/2019 - 11/2011
6	Irinotecan (Camptosar)FDA LinkGeneric 01/2018 - 04/2002
6	TOR Serine-Threonine KinasesIBA 09/2015 - 08/2006
6	Sirolimus (Rapamycin)FDA Link 04/2014 - 08/2006
6	Anticonvulsants (Antiepileptic Drugs)IBA 10/2010 - 01/2004
5	Protons (Proton)IBA 06/2022 - 03/2012
5	Oxygen (Dioxygen)IBA 05/2022 - 11/2018
5	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2013
5	Messenger RNA (mRNA)IBA 01/2016 - 07/2005
5	Adenosine Triphosphate (ATP)IBA 11/2015 - 12/2004
4	Phenylalanine (L-Phenylalanine)FDA Link 09/2021 - 07/2014
4	CholesterolIBA 01/2021 - 08/2009
4	Lapatinib (GW572016)FDA Link 10/2020 - 12/2009
4	Growth Factor ReceptorsIBA 12/2019 - 07/2015
4	LigandsIBA 01/2019 - 09/2002
4	tipifarnib (R115777)IBA 01/2018 - 09/2005
4	cabozantinibIBA 01/2018 - 01/2017
3	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
3	vocimagene amiretrorepvecIBA 12/2020 - 01/2016
3	Fatty Acids (Saturated Fatty Acids)IBA 10/2020 - 08/2009
3	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 12/2012
3	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2015
3	Lipase (Acid Lipase)FDA Link 01/2020 - 01/2018
3	LipidsIBA 01/2019 - 08/2010
3	Angiopoietin-2IBA 03/2018 - 05/2007
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018 - 12/2012
3	Monoclonal AntibodiesIBA 01/2017 - 09/2009
3	Phosphatidylinositols (Phosphatidylinositol)IBA 09/2015 - 06/2003
3	temsirolimus FDA Link 04/2014 - 12/2007
3	Peptides (Polypeptides)IBA 02/2013 - 08/2005
2	SolutionsIBA 10/2022 - 10/2011
2	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2022 - 01/2021
2	HexokinaseIBA 01/2022 - 01/2021
2	ivosidenibIBA 01/2022 - 10/2020
2	Dopamine AntagonistsIBA 01/2021 - 01/2020
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 01/2020
2	Atorvastatin (Lipitor)FDA Link 01/2021 - 12/2009
2	Flucytosine (Ancobon)FDA Link 12/2020 - 01/2016
2	tyrosine receptor (receptor, tyrosine)IBA 01/2020 - 04/2010
2	Epidermal Growth Factor (EGF)IBA 01/2020 - 12/2004
2	GDC-0084IBA 01/2020 - 01/2020
2	Oxidoreductases (Dehydrogenase)IBA 12/2019 - 12/2009
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019 - 11/2011
2	MicroRNAs (MicroRNA)IBA 01/2018 - 11/2014
2	Alanine Transaminase (SGPT)IBA 01/2018 - 08/2006
2	Glutamic Acid (Glutamate)FDA Link 07/2017 - 12/2012
2	afliberceptIBA 01/2017 - 07/2011
2	ParaffinIBA 01/2017 - 07/2013
2	pexidartinibIBA 01/2017 - 04/2016
2	Macrophage Colony-Stimulating FactorIBA 01/2017 - 04/2016
2	Liver X ReceptorsIBA 11/2016 - 10/2011
2	Contrast MediaIBA 11/2016 - 04/2014
2	Aspartate-Ammonia Ligase (Asparagine Synthetase)IBA 01/2016 - 05/2014
2	AsparagineIBA 01/2016 - 05/2014
2	O-(6)-methylguanineIBA 11/2015 - 01/2012
2	Transcription Factors (Transcription Factor)IBA 10/2015 - 10/2008
2	Mechanistic Target of Rapamycin Complex 1IBA 10/2013 - 08/2009

Therapy/Procedure

84	Therapeutics 10/2022 - 09/2002
16	Radiotherapy 01/2022 - 03/2004
12	Drug Therapy (Chemotherapy) 12/2020 - 05/2003
7	Chemoradiotherapy 11/2015 - 04/2010
6	Immunotherapy 06/2022 - 02/2013
5	Aftercare (After-Treatment) 01/2022 - 11/2014
2	Investigational Therapies (Experimental Therapy) 01/2022 - 11/2004